One of the questions that has been nagging at Howard Wolinsky for a while now is whether he really needs to have another biopsy … ever! … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: active surveillance, biopsy, low risk, monitoring, Wolinsky | 8 Comments »
The annual meeting of the American Urological Association (AUA) is one at which a great deal of information is exchanged, but a lot of that information is of limited utility to patients. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: active, atenolol, biopsy, genomic, MRI, PI-RADS, predict, prognosis, scan, surveillance, test | 4 Comments »
Cochrane reviews are structured, systematic, focused reviews of evidence in the field of medicine that either support or do not support specific forms of diagnosis and management of patients with or suspected of having particular disorders. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: accuracy, biopsy, Diagnosis, fusion, MRI, MRi-guided, MRI/TRUS, prognosis, scan | 3 Comments »
An article just published in Urologic Oncology has reported — perhaps not surprisingly — that men who have a single, initial negative biopsy as a consequence of suspicion of prostate cancer are at significant risk for actual diagnosis of prostate cancer over the next 20 years. … READ MORE …
Filed under: Uncategorized | Tagged: biopsy, Diagnosis, mortality, repeat, risk | 2 Comments »
Under the heading “Rats, my PSA went up. Do I need another bleeping biopsy?” Howard Wolinsky provides us with the latest “lowdown” on his 8-year-long prostate cancer journey on active surveillance. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: active, biopsy, MRI, repeat, surveillance | Leave a comment »
The prostate cancer research team led by Dr. Peter Pinto at the National Cancer Institute has just published some interesting new information on risk for disease progression in men on active surveillance. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, biopsy, follow-up, MRI/TRUS fusion, risk, surveillance | Leave a comment »
Last week we noted that adding MRI data to the Partin tables and to the Kattan/MSKCC nomograms did not seem to improve the accuracy of prognosis of outcomes after radical prostatectomy. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: biopsy, clinically significant, data, Gleason 7, MRI, outcome, PI-RADS, prediction, PSA, risk | 5 Comments »
It will come as no particular surprise that men who have had complications after a prior biopsy tend to be less enthusiastic when it is suggested that they need another one. However, … … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, compliance, complication, repeat | 8 Comments »
Many prostate cancer patients — and particularly those who don’t like the idea of prostate biopsies — think that if one uses MRI-guided biopsies alone one might only need to have one or two biopsy cores taken to accurately diagnose prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, cores, fusion, MRI, MRI/TRUS, number, scan | 7 Comments »
A new article in this week’s New England Journal of Medicine has just reported the full results of the so-called PRECISION trial of MRI-targeted vs. standard biopsy techniques in the diagnosis of prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, MRI, outcome, standard, targeted | 5 Comments »
The American Society of Clinical Oncology (ASCO) and the College of Pathologists (CAP) have just issued a joint review of available information on clinical use of “liquid biopsies” to assess circulating levels of tumor DNA (ctDNA). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: biopsy, circulating, ctDNA, DNA, liquid, review, test, tumor | 2 Comments »
Slowly but perhaps inexorably we seem to be seeing increasing scientific and clinical justification for the argument that all men thought to be at risk for a diagnosis of prostate cancer should be given an MRI scan prior to any form of prostate biopsy. … READ MORE …
Filed under: Diagnosis | Tagged: biopsy, cost, efficiency, MRI, standard | 8 Comments »
A recent report in Urology Practice makes what we see as a somewhat odd statement about what patients may be willing to pay for an MRI/TRUS fusion-guided biopsy as opposed to a TRUS-guided prostate biopsy. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: biopsy, cost, fusion, MRI | 4 Comments »
A newly published research letter in JAMA Oncology is entitled “Patient-paired sample congruence between 2 commercial liquid biopsy tests”. The two tests are both said — by the companies that market them — to have high clinical sensitivity and specificity in the identification of specific genetic markers associated with high-risk forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: biopsy, genetic, inconsistency, liquid, medicine, personalized, problem, result, test | 2 Comments »
